• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

随机试验评估利伐沙班与华法林在冠状动脉粥样硬化进展中的作用。

Randomized trial of rivaroxaban versus warfarin in the evaluation of progression of coronary atherosclerosis.

机构信息

Los Angeles Biomedical Research Center, Harbor-UCLA Medical Center, Torrance, CA.

Los Angeles Biomedical Research Center, Harbor-UCLA Medical Center, Torrance, CA.

出版信息

Am Heart J. 2018 Dec;206:127-130. doi: 10.1016/j.ahj.2018.08.007. Epub 2018 Aug 24.

DOI:10.1016/j.ahj.2018.08.007
PMID:30227941
Abstract

Warfarin, a vitamin K antagonist, is associated with systemic vascular calcification. We evaluated whether rivaroxaban (a direct oral factor Xa inhibitor with no interaction with vitamin K) will slow the progression in coronary plaque volumes compared with warfarin in patients with nonvalvular atrial fibrillation using coronary computed tomography angiography.

摘要

华法林是一种维生素 K 拮抗剂，与全身血管钙化有关。我们评估了使用冠状动脉计算机断层扫描血管造影术，与华法林相比，利伐沙班（一种直接口服的 Xa 因子抑制剂，与维生素 K 无相互作用）是否会减缓非瓣膜性心房颤动患者的冠状动脉斑块体积进展。

相似文献

1
Randomized trial of rivaroxaban versus warfarin in the evaluation of progression of coronary atherosclerosis.随机试验评估利伐沙班与华法林在冠状动脉粥样硬化进展中的作用。
Am Heart J. 2018 Dec;206:127-130. doi: 10.1016/j.ahj.2018.08.007. Epub 2018 Aug 24.
2
Apixaban versus warfarin in evaluation of progression of atherosclerotic and calcified plaques (prospective randomized trial).阿哌沙班与华法林在评估动脉粥样硬化和钙化斑块进展中的比较（前瞻性随机试验）。
Am Heart J. 2019 Jun;212:129-133. doi: 10.1016/j.ahj.2019.02.014. Epub 2019 Mar 13.
3
Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.达比加群、利伐沙班和阿哌沙班与华法林相比治疗非瓣膜性心房颤动的有效性和安全性。
J Am Heart Assoc. 2016 Jun 13;5(6):e003725. doi: 10.1161/JAHA.116.003725.
4
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).在每日口服一次利伐沙班、直接 Xa 因子抑制剂与维生素 K 拮抗剂预防心房颤动卒中及栓塞试验（ROCKET AF）中，与华法林相比，利伐沙班在老年非瓣膜性心房颤动患者中的疗效和安全性。
Circulation. 2014 Jul 8;130(2):138-46. doi: 10.1161/CIRCULATIONAHA.113.005008. Epub 2014 Jun 3.
5
Effects on bone metabolism markers and arterial stiffness by switching to rivaroxaban from warfarin in patients with atrial fibrillation.心房颤动患者从华法林转换为利伐沙班对骨代谢标志物和动脉僵硬度的影响。
Heart Vessels. 2017 Aug;32(8):977-982. doi: 10.1007/s00380-017-0950-2. Epub 2017 Feb 23.
6
Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial).心房颤动患者中风风险与体重指数的关系（来自利伐沙班与华法林治疗的患者，利伐沙班每日一次口服直接Xa因子抑制与维生素K拮抗剂预防心房颤动试验中的中风和栓塞试验）
Am J Cardiol. 2017 Jun 15;119(12):1989-1996. doi: 10.1016/j.amjcard.2017.03.028. Epub 2017 Mar 29.
7
Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial.利伐沙班在植入式心脏电子设备患者中的安全性和疗效：ROCKET AF 试验观察结果。
J Am Heart Assoc. 2017 Jun 14;6(6):e004663. doi: 10.1161/JAHA.116.004663.
8
Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).接受利伐沙班治疗非瓣膜性心房颤动时接受溶栓治疗的患者的结局（来自利伐沙班每日一次口服直接Xa因子抑制与维生素K拮抗剂预防心房颤动中风和栓塞试验）
Am J Cardiol. 2017 Nov 15;120(10):1837-1840. doi: 10.1016/j.amjcard.2017.07.095. Epub 2017 Aug 7.
9
Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).心房颤动患者的非中枢神经系统系统性栓塞：ROCKET AF研究结果（利伐沙班每日一次口服直接抑制Xa因子与维生素K拮抗剂预防心房颤动患者中风和栓塞的试验）
Circ Cardiovasc Qual Outcomes. 2017 May;10(5). doi: 10.1161/CIRCOUTCOMES.116.003520.
10
Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.非瓣膜性心房颤动且既往有卒中和短暂性脑缺血发作患者中应用阿哌沙班、达比加群和利伐沙班与华法林的有效性和安全性。
Stroke. 2017 Aug;48(8):2142-2149. doi: 10.1161/STROKEAHA.117.017474. Epub 2017 Jun 27.

引用本文的文献

1
Rivaroxaban versus vitamin K antagonist treatment on the progression of coronary calcification: the IRIVASC-trial.利伐沙班与维生素 K 拮抗剂治疗对冠状动脉钙化进展的影响：IRIVASC 试验。
Sci Rep. 2024 Jul 30;14(1):17605. doi: 10.1038/s41598-024-67657-8.
2
Trends in Off-Label Indications of Non-Vitamin K Antagonist Oral Anticoagulants in Acute Coronary Syndrome.急性冠状动脉综合征中非维生素K拮抗剂口服抗凝剂的超说明书用药指征趋势
Rev Cardiovasc Med. 2023 Jun 25;24(6):180. doi: 10.31083/j.rcm2406180. eCollection 2023 Jun.
3
Effects of Vitamin K2 and D Supplementation on Coronary Artery Disease in Men: A RCT.
补充维生素K2和D对男性冠状动脉疾病的影响：一项随机对照试验。
JACC Adv. 2023 Nov 24;2(9):100643. doi: 10.1016/j.jacadv.2023.100643. eCollection 2023 Nov.
4
Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis.非维生素 K 拮抗剂口服抗凝药（NOACs）在急性心肌梗死治疗中的应用：一项网状荟萃分析。
Cochrane Database Syst Rev. 2024 Jan 24;1(1):CD014678. doi: 10.1002/14651858.CD014678.pub2.
5
Atherosclerotic plaque stabilization and regression: a review of clinical evidence.动脉粥样硬化斑块的稳定和消退：临床证据回顾。
Nat Rev Cardiol. 2024 Jul;21(7):487-497. doi: 10.1038/s41569-023-00979-8. Epub 2024 Jan 4.
6
Interventions to Attenuate Cardiovascular Calcification Progression: A Systematic Review of Randomized Clinical Trials.干预措施以减轻心血管钙化进展：随机临床试验的系统评价。
J Am Heart Assoc. 2023 Dec 5;12(23):e031676. doi: 10.1161/JAHA.123.031676. Epub 2023 Nov 28.
7
Direct Oral Anticoagulants as the First Choice of Anticoagulation for Patients with Peripheral Artery Disease to Prevent Adverse Vascular Events: A Systematic Review and Meta-Analysis.直接口服抗凝剂作为外周动脉疾病患者预防不良血管事件的首选抗凝药物：一项系统评价和荟萃分析
J Cardiovasc Dev Dis. 2023 Feb 3;10(2):65. doi: 10.3390/jcdd10020065.
8
Vitamin K antagonists and cardiovascular calcification: A systematic review and meta-analysis.维生素K拮抗剂与心血管钙化：一项系统评价和荟萃分析。
Front Cardiovasc Med. 2022 Aug 19;9:938567. doi: 10.3389/fcvm.2022.938567. eCollection 2022.
9
Influence of rivaroxaban compared to vitamin K antagonist treatment upon development of cardiovascular calcification in patients with atrial fibrillation and/or pulmonary embolism.利伐沙班与维生素 K 拮抗剂治疗对伴有心房颤动和/或肺栓塞的患者心血管钙化发展的影响。
Clin Cardiol. 2022 Apr;45(4):352-358. doi: 10.1002/clc.23819. Epub 2022 Mar 25.
10
Warfarin involvement, in comparison to NOACs, in the development of systemic atherosclerosis.华法林与 NOACs 相比在全身性动脉粥样硬化发展中的作用。
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022 May;166(2):150-154. doi: 10.5507/bp.2022.008. Epub 2022 Feb 18.